Is It Safe? Safety Surveillance through the Antiretroviral Pregnancy Registry

Is It Safe? Safety Surveillance through the Antiretroviral Pregnancy Registry
Release Date: June 2, 2023
Expiration Date: June 2, 2024
Estimated Time to Complete: 1.25 hour

VIEW ACTIVITY

Clinical Gap and Educational Need

Antiretroviral therapy should be initiated for all persons with HIV who are pregnant regardless of CD4 count according to current guidelines. There is often minimal data available to make recommendations, however, for use in pregnancy. One key consideration is safety data that includes evaluating antiretroviral agents for birth defects. Using a combination of didactic presentation and case vignettes, this free CME/CNE-Certified webinar will review the importance of the Antiretroviral Pregnancy Registry (APR), a prospective, international registry that accepts voluntary reports of prenatal exposures by treating health care providers. The webinar will also explore how clinicians and their care teams can contribute to the success of the APR by registering patients and providing follow-up information on birth outcomes.

Learning Objectives

After participating in the activity, learners should be better able to:
Describe the objectives of the Antiretroviral Pregnancy Registry (APR) and its significance for teams caring for persons with HIV who are pregnant
Identify key findings from analysis of the APR and their implications for how the team cares for persons with HIV who are pregnant
Describe the four steps to report a drug exposure to the APR